Drug search by name

Didanosine Delayed-Release Enteric-Coated Capsules and Renal dysfunction

Result of checking the interaction of drug Didanosine Delayed-Release Enteric-Coated Capsules and disease Renal dysfunction for safety when used together.

Check result:

Didanosine Delayed-Release Enteric-Coated Capsules <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Didanosine (ddI) is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for ddI-related toxicity due to decreased drug clearance. Therapy with ddI should be administered cautiously at reduced dosages in patients with renal impairment.

References:

Singlas E, Taburet AM, Lebas FB, et al "Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis." Antimicrob Agents Chemother 36 (1992): 1519-24
"Product Information. Videx (didanosine)." Bristol-Myers Squibb, Princeton, NJ.

Didanosine Delayed-Release Enteric-Coated Capsules

Generic Name: didanosine

Brand Name: Videx, Videx EC

Synonyms: Didanosine

What is Didanosine Delayed-Release Enteric-Coated Capsules?